Forest Labs President Prefers Drug Partnerships, Not Big M&A
November 17 2009 - 12:26PM
Dow Jones News
Forest Laboratories Inc. (FRX) prefers to sign partnerships to
fill its pipeline ahead of a key patent expiration in 2012,
although it remains open to "tuck-in" acquisitions.
Lawrence Olanoff, president and chief operating officer of
Forest Labs, said partnerships allow the company to spread around
risk and cash, while sharing the costs of drug development. He made
the comments in an interview on the sidelines of the Lazard Capital
Markets health-care conference in New York.
He declined to comment on billionaire investor Carl Icahn's new
1 million share stake in Forest, which was reported in a filing
with the Securities and Exchange Commission late Monday. Icahn has
a history of interest in drug makers, confronting their management
and pushing for a strategy change or sale of the company.
Forest Lab shares slipped 22 cents Tuesday to $28.75.
Dr. Olanoff said the company doesn't comment on the intentions
of individual investors, but noted that Forest has a history of
dealing with large investors and they "are happy with our business
strategy going forward."
Part of that strategy for Forest, which tends to focus on
developing products rather than discovering them, is replacing the
revenue from its largest product, antidepressant Lexapro, which
makes up the majority of revenue but will face generic competition
in 2012.
Dr. Olanoff acknowledged that "2013 is going to be a down year
for us" and the company is focused on driving revenue growth in the
subsequent year by building its pipeline.
It plans to do that by filling its pipeline with products that
are partnered in order to share the costs and risks of development,
rather than taking a major bet on an acquisition.
"We would rather make a few smaller mistakes, rather than one
big mistake," Dr. Olanoff said.
- By Thomas Gryta, Dow Jones Newswires; 212-416-2169;
thomas.gryta@dowjones.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2023 to Sep 2024